Sign In
Buy AGNPF
$0.248
-0.0513 (-17.12%)
At Close: Jul 31, 2026
Algernon Pharmaceuticals: Meet the team that repurposes drugs to tackle life-threatening illnesses
04:33pm, Wednesday, 10'th Feb 2021
Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) is one of three emerging companies that will present at Proactive's virtual investor conference on Tuesday, February 16. Hosted by Proactive's Chri
Algernon Pharmaceuticals mulls lung scarring as additional endpoint for Phase 2b/3 coronavirus trial of Ifenprodil
09:06am, Wednesday, 10'th Feb 2021
Algernon Pharmaceuticals Inc (CSE:AGN) (FRA:AGW) (OTCQB:AGNPF) is evaluating the protocol for its Phase 2b/3 study of Ifenprodil for coronavirus (COVID-19), to consider adding lung scarring as an addi
Algernon Pharmaceuticals mulls lung scarring as additional endpoint for Phase 2b/3 COVID-19 trial of Ifenprodil
08:34am, Wednesday, 10'th Feb 2021
Algernon Pharmaceuticals Inc (CSE:AGN) (FRA:AGW) (OTCQB:AGNPF) is evaluating the protocol for its Phase 2b/3 study of Ifenprodil for COVID-19, to consider adding lung scarring as an additional endpoin
Algernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study Protocol
07:00am, Wednesday, 10'th Feb 2021
VANCOUVER, British Columbia, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmace
Algernon Pharmaceuticals inks deal with Charles River Laboratories for preclinical work on DMT for stroke
09:33am, Monday, 08'th Feb 2021
Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) (FRA:AGW), the drug repurposing company, said pre-clinical studies on the psychedelic compound DMT to treat stroke will be carried out at the Charl
Algernon Pharmaceuticals Signs Agreement with Charles River Laboratories for DMT Preclinical Studies
08:05am, Monday, 08'th Feb 2021
VANCOUVER, British Columbia, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmace
Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic Drug DMT “The Spirit Molecule”
07:30am, Monday, 01'st Feb 2021
VANCOUVER, British Columbia, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmace
Algernon Pharmaceuticals Provides Final Summary on Accelerated Warrants
12:14pm, Friday, 22'nd Jan 2021
VANCOUVER, British Columbia, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmace
Algernon Pharmaceuticals Provides Reminder on Expiry Date of Accelerated Warrants
12:00pm, Tuesday, 19'th Jan 2021
VANCOUVER, British Columbia, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmace
Algernon Pharmaceuticals Receives Green Light from DSMB to Conduct Phase 3 Study of Ifenprodil for COVID-19
08:03am, Tuesday, 19'th Jan 2021
VANCOUVER, British Columbia, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmace
Algernon Pharmaceuticals Provides Year End Summary of Key Activities
08:00am, Wednesday, 30'th Dec 2020
VANCOUVER, British Columbia, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmace
Algernon Pharmaceuticals Announces Last Patient Out in Multinational Phase 2b/3 Human Study of Ifenprodil for COVID-19
11:42am, Thursday, 24'th Dec 2020
VANCOUVER, British Columbia, Dec. 24, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceu
Algernon Pharmaceuticals Announces Acceleration of Expiry Date of Warrants
07:40pm, Wednesday, 23'rd Dec 2020
VANCOUVER, British Columbia, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmace
Algernon Pharmaceuticals Provides Additional Information on Phase 2b/3 Ifenprodil COVID-19 Study Interim Data
08:00am, Thursday, 17'th Dec 2020
VANCOUVER, British Columbia, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmace
Algernon CEO and CSO to Discuss COVID-19 Interim Data Results Featured on BioPub Webcast Hosted by Dr. KSS MD PhD
07:44pm, Wednesday, 16'th Dec 2020
VANCOUVER, British Columbia, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmac
